Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
Links relacionados
- Similares en SciELO
Compartir
Medicina (Buenos Aires)
versión impresa ISSN 0025-7680versión On-line ISSN 1669-9106
Resumen
AMERISO, Sebastián F. y PUJOL LEREIS, Virginia A.. Neurological perspective in the choice of direct oral an ticoagulants for prevention of stroke in atrial fibrillation. Medicina (B. Aires) [online]. 2023, vol.83, n.2, pp.273-277. ISSN 0025-7680.
Non-valvular atrial fibrillation (AF) is the most preva lent arrhythmia with high embolic potential, and one of the main and growing causes of stroke. The main objec tive of anticoagulation in patients with AF is prevention of stroke. Until recently, anticoagulation with vitamin K antagonists (VKAs) was the only available option. Direct oral anticoagulants (DOACs), such as the direct thrombin inhibitor dabigatran, or the direct factor Xa inhibitors rivaroxaban, apixaban, and edoxaban, have a more favor able effectiveness/safety profile compared to VKAs. There are no studies comparing the efficacy of DOACs with each other. The choice of a DOAC arose from patient car achterictis, physician preferences, cost, and accessibility. Between 1-2% of patients correctly treated with a DOAC experience a stroke each year. The possibility of having a reversal agent should be taken into account when choos ing a DOAC, especially due to the residual risk of stroke occurrences even under DOACs. Currently, in our country only dabigatran has a reversing agent available, making it the only DOAC that does not contraindicate the use of intravenous thrombolysis. This should be taken into account when choosing the DOAC for the prevention of thromboembolic events in patients with AF.
Palabras clave : Ischemic stroke; Intravenous thromboly sis; Direct anticoagulants; Atrial fibrillation; Rational indication.